Alpha DNA Investment Management LLC Buys New Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Alpha DNA Investment Management LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 12,218 shares of the specialty pharmaceutical company's stock, valued at approximately $442,000.

Other institutional investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $52,000. Headlands Technologies LLC boosted its stake in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth about $72,000. Finally, Venturi Wealth Management LLC bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $92,000.

Analyst Ratings Changes

SUPN has been the topic of several recent research reports. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN traded up $0.31 during trading hours on Thursday, hitting $31.15. The company's stock had a trading volume of 88,646 shares, compared to its average volume of 566,912. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The company's 50 day simple moving average is $32.25 and its two-hundred day simple moving average is $34.98. The company has a market cap of $1.74 billion, a P/E ratio of 29.12 and a beta of 0.90.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. This represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 in the last 90 days. 9.30% of the stock is currently owned by insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.